Meta-analysis of smoking cessation medications on continuous abstinence rate at 1 year

Main Article Content

Worawan Minphimai
Onanong Waleekhachonloet
Supon Limwattananon
Chulaporn Limwattananon


Introduction: The aim of this study was to systematically review studies on smoking cessation medications and to conduct meta-analysis of efficacy of the first-line drugson continuous abstinence rate (CAR) at 1 year. Materials and Method: MEDLINE was searched from an inception to January 2015. Only studies using RCT design were selected. Primary outcome was a continuous abstinence at 1 year, confirmed by end-expiration carbon monoxide level ≤ 10 ppm or urinary cotinine level < 60 ng/ml. Results: Six studies of 4,456patients that passed selection criteria were included for the meta-analysis. All studies had high quality with Jadad score of 5. Varenicline and Bupropion contributed to a significantly higher CAR than placebo (OR, 2.56; 95% CI, 1.98-3.31 and OR, 1.86; 95% CI, 1.47-2.36, respectively). Comparing between the two drugs, Varenicline was more efficacious than Bupropion(OR,1.66; 95% CI,1.27-2.15). Conclusion: Our study confirmed the efficacy of both Varenicline and Bupropion over the placebo control and a higher efficacy of Vareniclinethan Bupropion in smoking cessation for one year.

Article Details

Pharmaceutical Practice


Cahill K, Stevens S, Perera R, Lancaster T.Pharmacological interventions for smokingcessation: an overview and network meta-analysis(Review). Cochrane Database of Systematic Reviews 2013;5: CD009329.

Caraballo RS, Kruger J, Asman K, et al. Relapse among cigarette smokers: the CARDIA longitudinal study-1985-2011. Addict Behav 2014; 39(1): 106.

Fossati R, Apolone G, Negri E, et al. A double-blind, placebo-controlled, randomized trial of Bupropion for smoking cessation in primary care. Arch Intern Med; 2007; 167(16):1791-7.

Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2nicotinic acetylcholine receptor partial agonist, vssustained-release Bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1): 47-55.

Gonzales D, Jorenby DE, Brandon TH, Arteaga C, Lee TC. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with Varenicline, Bupropion SR or placebo. Addiction2010; 105(11): 2002-13.

Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the British household panel survey. NicotineTob Res 2010; 12: 1228-35.

Higgins JPT, Thomson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ2003;327: 557-60.

HughesJR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence Inclinical trials: issues and recommendations. Nicotine& Tobacco Research2003; 5, 13–25.

Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews2014; 1: CD000031.

Jadad R, Moore RA, Carrol D, et al. Assessing the quality of reportsof randomized clinical trails: Is blinding necessary? Control Clinical Trials1996; 17: 1-12.

Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release Bupropion for smoking cessation: a randomized controlled trial. JAMA2006;296(1): 56-63.

Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of Varenicline, an alpha4beta2nicotinicacetylcholinereceptor partial agonist, in a12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. ClinTher2007; 29(6):1040-56.

Nides M, Oncken C, Gonzales D, et al. Smoking cessation with Varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and Bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166(15): 1561-8.

Piasecki TM. Relapse to smoking. Clinical Psychology Review2006; 26: 196–215.

Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of Bupropion SR for smoking cessation. J Intern Med2003;254(2):184-92.

Velicer WF, Prochaska JO, Rossi JS, Snow MG. Assessing outcome in smoking cessation studies. Psychol Bull 1992; 111(1): 23-41.

Velicer WF, Prochaska JO. A comparison of four self-report smoking cessation outcome measures. Addictive Behaviors2004; 29: 51-60.